{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:21:24Z","timestamp":1791379284733,"version":"4.3.2"},"reference-count":12,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nCannabidiol (CBD), a non-intoxicating compound derived from Cannabis sativa, has gained widespread popularity for its proposed therapeutic effects in conditions such as anxiety, insomnia, and chronic pain. Unlike tetrahydrocannabinol (THC), CBD is often perceived as safe, with minimal psychoactive properties. However, its psychiatric safety profile, particularly in relation to mood disorders, remains poorly understood.\nCase Presentation\nWe report the case of a 31-year-old male with no prior psychiatric history who developed a manic episode characterized by irritability, decreased need for sleep, hyperactivity, and aggression. These symptoms emerged after three months of escalating daily CBD use via vaping, reaching high doses shortly before admission. Toxicology screening was negative for other substances, and the patient showed clinical improvement with mood stabilizers and antipsychotics following the discontinuation of CBD.\nDiscussion\nThis case raises concerns about the potential of high-dose CBD to induce manic symptoms in certain individuals. While CBD has been proposed to have anxiolytic and antipsychotic effects, its influence on mood regulation may be complex and dose-dependent. The variability in commercial CBD product composition, including possible contamination or mislabeling, further complicates risk assessment. Current evidence from clinical trials on CBD\u2019s effects in mood disorders is limited and inconclusive.\nConclusion\nClinicians should remain alert to the psychiatric effects of CBD, particularly in patients presenting with new-onset mood symptoms. This report underscores the need for controlled studies to assess the safety of CBD in psychiatric populations and calls for stricter regulation of cannabinoid products.<\/jats:p>","DOI":"10.64719\/pb.4542","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"116-122","source":"Crossref","is-referenced-by-count":1,"title":["Cannabidiol Induced Manic Episode: A Case Report"],"prefix":"10.64719","volume":"55","author":[{"given":"Anas Ibn","family":"Auf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan A","family":"Almakki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora M","family":"Alhummayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci.. 2016;7:19. doi: 10.3389\/fpls.2016.00019.","DOI":"10.3389\/fpls.2016.00019"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther.. 2017;175:133\u2013150. doi: 10.1016\/j.pharmthera.2017.02.041.","DOI":"10.1016\/j.pharmthera.2017.02.041"},{"key":"ref3","unstructured":"WebMD. 2019 Cannabidiol (CBD): Uses, side effects, interactions, dosage, and warning [Internet] [cited 2025 May 30]. Available from: https:\/\/www.webmd.com\/vitamins\/ai\/ingredientmono-1439\/cannabidiol-cbd."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Schouten M, Dalle S, Mantini D, Koppo K. Cannabidiol and brain function: Current knowledge and future perspectives. Front Pharmacol.. 2024;14:1328885. doi: 10.3389\/fphar.2023.1328885.","DOI":"10.3389\/fphar.2023.1328885"},{"key":"ref5","unstructured":"Grinspoon P. Cannabidiol (CBD): what we know and what we don\u2019t [Internet] 2024 Harvard Health Blog. [cited 2025 May 30]. Available from: https:\/\/www.health.harvard.edu\/blog\/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Khan R, Naveed S, Mian N, Fida A, Raafey MA, Aedma KK. The therapeutic role of cannabidiol in mental health: A systematic review. J Cannabis Res.. 2020;2(1):6. doi: 10.1186\/s42238-019-0012-y.","DOI":"10.1186\/s42238-019-0012-y"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Pinto JV, Ziak ML, Schaffer A, Yatham LN. Cannabidiol in the treatment of mood disorders. Curr Treat Options Psychiatry. 2022;9:140\u2013150. doi: 10.1007\/s40501-022-00265-3.","DOI":"10.1007\/s40501-022-00265-3"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282\u2013298. doi: 10.1016\/j.neuro.2019.08.002. doi:","DOI":"10.1016\/j.neuro.2019.08.002"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Arjmand S, Behzadi M, Kohlmeier KA, Mazhari S, Sabahi A, Shabani M. Bipolar disorder and the endocannabinoid system. Acta Neuropsychiatr. 2019;31(4):193\u2013201. doi: 10.1017\/neu.2019.21.","DOI":"10.1017\/neu.2019.21"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K, Chakrabarty T et al. Cannabidiol as a treatment for mood disorders: a systematic review. Can J Psychiatry.. 2019;65(4):213\u2013227. doi: 10.1177\/0706743719895195.","DOI":"10.1177\/0706743719895195"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Miranda A, Holloway BM, Perry W, Minassian A, McCarthy M. Co-morbid cannabis use disorder and chronotype are associated with mood symptom onset in people with bipolar disorder. J Psychiatr Res.. 2024;180:327\u2013332. doi: 10.1016\/j.jpsychires.2024.11.007.","DOI":"10.1016\/j.jpsychires.2024.11.007"},{"key":"ref12","unstructured":"U.S. Food and Drug Administration. 2021 Warning letters and test results for cannabidiol-related products [Internet] [cited 2025 May 30]. Available from: https:\/\/www.fda.gov\/news-events\/public-health-focus\/warning-letters-and-test-results-cannabidiol-related-products."}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:41Z","timestamp":1791315221000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/cannabidiol-induced-manic-episode-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4542","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}